Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification

Clinical and Investigative Medicine

Volumn 26, Issue 4, 2003, Pages 158-165

  Grewal, Jasmine ^a   Chan, Sammy ^a   Frohlich, Jiri ^a   Mancini, G B John ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ANAMNESIS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CAROTID ARTERY; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE MARKER; ECHOGRAPHY; FEMALE; FRAMINGHAM RISK STRATIFICATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; OUTPATIENT DEPARTMENT; PATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; E-SELECTIN; FEMALE; HOMOCYSTEINE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTORS; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR;

EID: 0141638737     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dawber TR, Kannel WB. The Framingham Study. An epidemiological approach to coronary heart disease. Circulation 1966;34:553-5.
2. Ridker PM, Cushman M, Stamper MJ. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
3. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
4. Hwang SJ, Ballantyne CM, Sharrett AR. Circulating adhesion molecules VCAM-1 ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities study. Circulation 1997;96:4219-25.
5. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentrations of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.
6. Goto S. Role of von Willebrand factor for the onset of arterial thrombosis [review]. Clin Lab 2001;47:327-34.
7. McCully KS. Vascular pathology of homocysteinemia; implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
8. Suwaidi JA, Hamasaki S, Higano ST. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
9. Celermajer DS, Sorenson KE, Gooch VM. Non-invasive detection of endothelial dysfunction in children and adults at risk of arteriosclerosis. Lancet 1992;340:1111-5.
10. Belcaro G, Nicolaides AN, Laurora G, Cesarone MR, De Sanctis M, Incandela L, et al. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vasc Biol 1996;16:851-6.
11. Mancini GB, Chan S, Frohlich J, Kuramoto L, Schulzer M, Abbott D. Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction. Am J Cardiol 2002;89:1313-6.
12. Bressler B, Chan S, Mancini GB. Temporal response of brachial artery dilation after occlusion and nitroglycerin. Am J Cardiol 2000;85:396-400.
13. Aminbakhsh A, Frohlich J, Mancini GB. Detection of early atherosclerosis with B mode ultrasonography: assessment of a new quantitative approach. Clin Invest Med 1999;22:265-73.
14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement from healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
15. Hodis H, Mack WJ, LaBree L, Selzer RH. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9.
16. Mitchell JR, Schwartz CJ. Relationship between arterial disease at different sites. BMJ 1962;1:1293-301.
17. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
18. Harker LA, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
19. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest 1996;98:24-9.
20. Van Den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995;24:176-81.
21. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000;160:422-34.
22. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
23. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
24. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
25. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
26. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.
27. Poston RN, Haskard DO, Coucher JR, Gall NP. Expression of the adhesion molecule ICAM-1 in atherosclerotic plaques: implications for positive feedback monocyte recruitment in the pathogenesis of plaque. Am J Pathol 1992;140:665-73.
28. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
29. Springer TA. Traffic signals for lymphocyte recirculation and leucocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
30. Nageh MF, Sanderberg ET, Marotti KR. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997;17:1517-20.
31. Malik I, Danesh J, Whincup P. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-5.
32. Koenig W, Sund M, Frohlich M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
33. Danesh J, Whincup P, Walker M. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
34. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
35. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
36. Vita JA, Treasure CB, Nabel EG. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-7.
37. Glasser SP, Selwyn AP, Ganz P. Atherosclerosis: risk factors and the vascular endothelium. Am Heart J 1996;131:379-84.
38. Celermajer DS, Sorenson KE, Bull C, Robinson J. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-74.
39. Neunteufl T, Heher S, Katzenschlager R. Late prognostic value of flow mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-10.
40. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
41. Perticone F, Ceravolo R, Pujia A. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-201.
42. Heitzer T, Schlinzig T, Krohn K. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8.
43. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Texcaps. JAMA 1998;279:1615-22.
44. Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.